# Internal Review (Claude Code) — Round 1

**Date:** 2026-02-03
**Reviewer:** Claude Code (claude-opus-4-5)
**Paper:** State Insulin Copay Cap Laws and Diabetes Mortality

## Summary

This revision of apep_0150 substantially addresses the fatal errors identified by the Gemini advisor and code integrity issues from the scanner. The paper uses modern staggered DiD methods (Callaway-Sant'Anna, Sun-Abraham, TWFE) to estimate the effect of state insulin copay cap laws on diabetes mortality. The main finding is a well-characterized null result, with thorough power analysis demonstrating that the design is underpowered to detect plausible effects due to outcome dilution.

## Key Improvements from Parent Paper
1. Table 1 (summary statistics) populated with real data
2. COVID death rate rescaled to per 100,000 for interpretable coefficients
3. Log specification sign correctly discussed (positive coefficient = slight increase, not reduction)
4. Figure 1 annotated with not-yet-treated states
5. Code fixes: COVID=0 fallback changed to NA, method fallback logged, balance table fixed
6. Added MDE analysis, placebo-in-time tests, anticipation leads
7. Added references (Keating 2024, Roth 2022, Onder 2020, Athey & Imbens 2022, etc.)

## Remaining Issues
1. Wild cluster bootstrap unavailable (R package incompatibility) — documented as limitation
2. HonestDiD uses diagonal VCV approximation — documented with conservative interpretation
3. 2018-2019 data gap not filled — acknowledged limitation
4. Placebo outcomes lack post-treatment variation — acknowledged limitation

## Verdict

The paper is well-written, methodologically sound, and transparent about limitations. The null result is informative and properly contextualized. The revision successfully addresses the critical issues from the parent paper.

**DECISION: MINOR REVISION** (proceed to external review)
